Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 8/20 | 0.59 |
| ▸ | CACNA2D1 | P54289 | 5/20 | 0.58 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.58 |
| ▸ | CACNB1 | Q02641 | 5/20 | 0.58 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.58 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1375212 | 0.88 | CACNA1G (0.57) | CACNA1GCACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL31350801 | 0.87 | CACNA2D1 (0.67) | CACNA1GCACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL18263736 | 0.86 | KMT2A (0.71) | CACNA1GCACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL18271350 | 0.86 | KMT2A (0.71) | CACNA1GCACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL18263701 | 0.86 | KMT2A (0.71) | CACNA1GCACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL12431993 | 0.85 | CACNA1G (0.59) | CACNA1GCACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL18271367 | 0.84 | KMT2A (0.48) | CACNA1GCACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL21663512 | 0.84 | KMT2A (0.56) | CACNA1GCACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL1377935 | 0.84 | CACNA1G (0.60) | CACNA1GCACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL12150956 | 0.84 | CACNA1G (0.60) | CACNA1GCACNA2D1CACNA1BCACNB1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275810-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2011-11-10 | — | — | US | disclosed |
| US-7981895-B2 | Histone deacetylase inhibitor; anticancer agents; antiproliferative agents; antitumor agents; psoriasis; piperazine compound containing a carbamic acid group | TOPOTARGET UK LIMITED (GB) | 2011-07-19 | — | — | US | disclosed |
| US-7629343-B2 | Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| US-20080269237-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2008-10-30 | — | — | US | disclosed |
| EP-1492534-B1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LTD (GB) | 2008-06-25 | — | — | EP | disclosed |
| US-20050143385-A1 | Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors | TOPOTARGET UK LIMITED (GB) | 2005-06-30 | — | — | US | disclosed |
| EP-1492534-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TopoTarget UK Limited (GB) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082288-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143385-A1 | Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors | HDAC1, HDAC7, HDAC11 | CACNA1G 3223/4885CACNA2D1 2520/4885CACNA1B 3971/4885 |
| US-20080269237-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | HDAC5, HDAC1, HDAC7 | CACNA1G 3528/4885CACNA2D1 1827/4885CACNA1B 3376/4885 |
| US-20110275810-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | HDAC5, HDAC1, HDAC7 | CACNA1G 3528/4885CACNA2D1 1827/4885CACNA1B 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.